Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive care

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 1027-1030

  Sung, Lillian ^a   Zaoutis, Theo ^b   Ullrich, Nicole J ^c   Johnston, Donna ^d   Dupuis, Lee ^a   Ladas, Elena ^e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e Department of Medicine   (United States)

Author keywords

Cancer control; Cognition; Infection; Supportive care

Indexed keywords

CAPHOSOL; CASPOFUNGIN; CHLORHEXIDINE GLUCONATE; CYPROHEPTADINE; DEXAMETHASONE; FIDAXOMICIN; FLUCONAZOLE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; HOMEOPATHIC AGENT; LEVOFLOXACIN; MODAFINIL; ONDANSETRON; TRAUMEEL S; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BACTEREMIA; BLOODSTREAM INFECTION; CACHEXIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RESEARCH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITION; COGNITIVE DEFECT; COLITIS; DROWSINESS; FEBRILE NEUTROPENIA; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; INFECTION; INFECTION CONTROL; INFLAMMATION; MYCOSIS; NEUTROPENIA; NUTRITION; ORAL MUCOSITIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DELIVERY OF HEALTH CARE; HUMANS; INFECTION; NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RESEARCH;

EID: 84876440490     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24426     Document Type: Review

References (35)

1. Alexander S, Nieder M, Zerr DM, et al. Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn? Pediatr Blood Cancer 2012; 59: 16-20.
2. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data. Pediatr Blood Cancer 2012; 59: 21-26.
3. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer 2009; 115: 1100-1108.
4. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532-3539.
5. Sung L, Aplenc R, Alonzo TA, et al. Severe toxicities during pediatric acute myeloid leukemia chemotherapy: A report from the Children's Oncology Group. Abstract presented at: American Society of Hematology Conference; December 2010; Orlando, Florida.
6. Sung L, Buxton A, Gamis A, et al. Life-threatening and fatal infections in children with acute myeloid leukemia. J Pediatr Hematol Oncol 2011; 34: e30-e35.
7. Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400-411.
8. Ozkaynak MF, Krailo M, Chen Z, et al. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2005; 45: 274-280.
9. Sonis ST. Oral complications of cancer chemothrapy in pediatric patients. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practices of oncology, 4th edition. Philadelphia: Lippincott; 1993. pp. 2385-2394.
10. Ethier MC, Regier DA, Tomlinson D, et al. Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer. Support Care Cancer 2012; 20: 1771-1777.
11. Sencer SF, Zhou T, Freedman LS, et al. Traumeel S in preventing and treating mucositis in young patients undergoing SCT: A report of the Children's Oncology Group. Bone Marrow Transplant 2012; 47: 1409-1414.
12. Sands SA, Zhou T, O'Neil SH, et al. Long-term follow-up of children treated for high-grade gliomas: Children's oncology group L991 final study report. J Clin Oncol 2012; 30: 943-949.
13. Kadan-Lottick NS, Brouwers P, Breiger D, et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 5986-5992.
14. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009; 114: 1746-1752.
15. Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 2012; 104: 1386-1395.
16. Waber DP, Queally JT, Catania L, et al. Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer 2012; 58: 758-765.
17. Klassen AF, Anthony SJ, Khan A, et al. Identifying determinants of quality of life of children with cancer and childhood cancer survivors: A systematic review. Support Care Cancer 2011; 19: 1275-1287.
18. Sung L, Klaassen RJ, Dix D, et al. Identification of paediatric cancer patients with poor quality of life. Br J Cancer 2009; 100: 82-88.
19. Buchanan N, Maloney K, Tsang S, et al. Risk of depression, anxiety, and somatization one month after diagnosis in children with standard risk ALL on COG AALL 033. J Clin Oncol (Meeting Abstracts) 2008; 26: suppl 10052.
20. Nagarajan R, Andreas W, Calaminus G. Quality of life assessment of patients undergoing therapy for osteosarcoma in the European American Osteosarcoma Study (EURAMOS): Feasibility. Pediatr Blood Cancer 2009; 53: 794 (PD.014).
21. Nagarajan R, Wiener A, Hjorth L, et al. Quality of life (QOL) assessment of patients undergoing therapy for osteosarcoma in the European American Osteosarcoma Study (EURAMOS): Feasibility. 2009. Annual Meeting; Sao Paulo, Brazil.
22. Wiener A, Nagarajan R, Hjorth L, et al. Quality of life (QOL) in osteosarcoma: First results of the pre surgery treatment period of EURAMOS-1 (NCT00134030). 2010. Annual Meeting; Chicago, IL.
23. Wiener A, Nagarajan R, Hjorth L, et al. Quality of life (QOL) in osteosarcoma: Preliminary results of the initial treatment period of EURAMOS-1 (NCT00134030). 2011. Annual Meeting; Chicago, IL.
24. Johnston DL, Nagel K, Friedman DL, et al. Availability and use of palliative care and end-of-life services for pediatric oncology patients. J Clin Oncol 2008; 26: 4646-4650.
25. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293: 203-211.
26. Orgel E, Sposto R, Malvar J, et al. Extremes of weight are associated with increased treatment-related toxicity in high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. 2011. 53rd Annual Meeting and Symposium; San Diego, CA.
27. Couluris M, Mayer J, D F, et al. The effect of cyproheptadine hydrochloride (Periactin®) and megestrol acetate (Megace®) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol 2008; 30: 791-797.
28. Dupuis LL, Milne-Wren C, Cassidy M, et al. Symptom assessment in children receiving cancer therapy: The parents' perspective. Support Care Cancer 2010; 18: 281-299.
29. Dupuis L, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2011; 57: 191-198.
30. POGO. 2012 September 25. Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients. http://www.pogo.ca/healthcare/practiceguidelines/. Accessed 2012 September 25.
31. Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: A systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106: 1626-1637.
32. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol 2004; 22: 1222-1227.
33. Tomlinson D, Gibson F, Treister N, et al. Refinement of the Children's International Mucositis Evaluation Scale (ChIMES): Child and parent perspectives on understandability, content validity and acceptability. Eur J Oncol Nurs 2010; 14: 29-41.
34. Tomlinson D, Gibson F, Treister N, et al. Understandability, content validity, and overall acceptability of the Children's International Mucositis Evaluation Scale (ChIMES): Child and parent reporting. J Pediatr Hematol Oncol 2009; 31: 416-423.
35. Wu HS, Davis JE, Natavio T. Fatigue and disrupted sleep-wake patterns in patients with cancer: A shared mechanism. Clin J Oncol Nurs 2012; 16: E56-E68.